Woojin Jung

Woojin Jung

Auto-generated profile, based on publicly available information

Woojin Jung

Senior Health Convergence Research Center, Chungnam National University, Daejeon, Republic of Korea

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
WJWoojin Jung
Woojin Jung
SGSungwoo Goo
Sungwoo Goo
THTaewook Hwang
Taewook Hwang
HLHyunjung Lee
Hyunjung Lee
Young Kuk KimYoung Kuk Kim
Young Kuk Kim
SJSangkeun Jung
Sangkeun Jung
Machine learning techniques are extensively employed in drug discovery, with a significant focus on developing QSAR models that interpret the structural information of potential drugs. In this study, the pre-trained natural language processing (NLP) model, ChemBERTa, was utilized in the drug discovery process. We proposed and evaluated four core model architectures as follows: deep neural network (DNN), encoder, concatenation (concat), and pipe. The DNN model processes physicochemical properties as input, while the encoder model leverages the simplified molecular input line entry system (SMILES) along with NLP techniques. The latter two models, concat and pipe, incorporate both SMILES and physicochemical properties, operating in parallel and with sequential manners, respectively. We collected 5238 entries from DrugBank, including their physicochemical properties and absorption, distribution, metabolism, excretion, and toxicity (ADMET) features. The models’ performance was assessed by the area under the receiver operating characteristic curve (AUROC), with the DNN, encoder, concat, and pipe models achieved 62.4%, 76.0%, 74.9%, and 68.2%, respectively. In a separate test with 84 experimental microsomal stability datasets, the AUROC scores for external data were 78% for DNN, 44% for the encoder, and 50% for concat, indicating that the DNN model had superior predictive capabilities for new data. This suggests that models based on structural information may require further optimization or alternative tokenization strategies. The application of natural language processing techniques to pharmaceutical challenges has demonstrated promising results, highlighting the need for more extensive data to enhance model generalization.

26 February 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SRSunae Ryu
Sunae Ryu
WJWoo Jin Jung
Woo Jin Jung
Zheng JiaoZheng Jiao
Zheng Jiao
Jung-woo ChaeJung-woo Chae
Jung-woo Chae
HYHwi-yeol Yun
Hwi-yeol Yun

1 January 2021 in Clinical Therapeutics
Verified
Journal Article
Closed access
WJWoo Jin Jung
Woo Jin Jung
JPJung-Hyuck Park
Jung-Hyuck Park
SGSungwoo Goo
Sungwoo Goo
JCJung-Woo Chae
Jung-Woo Chae
JKJaeWoo Kim
JaeWoo Kim
HYHwi-yeol Yun
Hwi-yeol Yun

21 May 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
HJHye Seon Jeon
Hye Seon Jeon
SLSang Won Lee
Sang Won Lee
WJWoojin Jung
Woojin Jung
HJHeeyoon Jung
Heeyoon Jung
DCDonghoon Choi
Donghoon Choi
Howard LeeHoward Lee
Howard Lee
Recombinant human interleukin‐7 hybrid Fc (rhIL‐7‐hyFc) is a homodimer of rhIL‐7 fused to a hyFc. Exogenous IL‐7 promotes T cell proliferation and increases lymphocyte count, making it a potential treatment option for lymphopenia and cancer. To improve therapeutic efficacy, rhIL‐7‐hyFc was developed as a long‐acting IL‐7. This study aimed to create a pharmacokinetic model for rhIL‐7‐hyFc by incorporating neonatal Fc receptor (FcRn)‐mediated recycling and target‐mediated drug disposition (TMDD) of the IL‐7 receptor. Data were collected from a randomized, double‐blind, placebo‐controlled phase 1 trial involving 30 healthy volunteers who received single doses of rhIL‐7‐hyFc. Volunteers received 20 or 60 mg/kg subcutaneously, 60 mg/kg intramuscularly (IM), or a placebo. Clinical data were provided by Genexine Inc. (Seoul, Republic of Korea). A TMDD‐FcRn–mediated recycling pharmacokinetic model was developed using NONMEM 7.5 software, assisted by PsN 5.3.1 software. A quasi‐steady‐state approximation was used to describe drug‐receptor and drug‐FcRn interactions. The model evaluation included goodness of fit, visual predictive checks, and bootstrap analysis. Based on the pharmacokinetic parameters of the final model, a simulation was conducted to select the dosage regimen, ensuring a probability of at least 0.8 for meeting both safety and efficacy criteria. The model successfully described the pharmacokinetic profiles of 24 patients administered rhIL‐7‐hyFc. Based on the simulation results, 670–800 μg/kg every 3 weeks, 1010–1530 μg/kg every 6 weeks, and 1510–2190 μg/kg every 9 weeks IM were proposed. These results may help further understand rhIL‐7‐hyFc characteristics and, moreover, provide guidance for selecting the appropriate dosing regimen in future clinical trials.

20 January 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
WJWoojin Jung
Woojin Jung
HJHeeyoon Jung
Heeyoon Jung
NVNgoc-Anh Thi Vu
Ngoc-Anh Thi Vu
GKGwanyoung Kim
Gwanyoung Kim
GKGyoung-Won Kim
Gyoung-Won Kim
HYHwi-yeol Yun
Hwi-yeol Yun
Donepezil patch was developed to replace the original oral formulation. To accurately describe the pharmacokinetics of donepezil and investigate compatible doses between two formulations, a population pharmacokinetic model for oral and transdermal patches was built based on a clinical study. Plasma donepezil levels were analyzed via liquid chromatography/tandem mass spectrometry. Non-compartmental analyses were performed to derive the initial parameters for compartmental analyses. Compartmental analysis (CA) was performed with NLME software NONMEM assisted by Perl-speaks-NONMEM, and R. Model evaluation was proceeded via visual predictive checks (VPC), goodness-of-fit (GOF) plotting, and bootstrap method. The bioequivalence test was based on a 2 × 2 crossover design, and parameters of AUC and Cmax were considered. We found that a two-compartment model featuring two transit compartments accurately describes the pharmacokinetics of nine subjects administered in oral, as well as of the patch-dosed subjects. Through evaluation, the model was proven to be sufficiently accurate and suitable for further bioequivalence tests. Based on the bioequivalence test, 114 mg/101.3 cm2–146 mg/129.8 cm2 of donepezil patch per week was equivalent to 10 mg PO donepezil per day. In conclusion, the pharmacokinetic model was successfully developed, and acceptable parameters were estimated. However, the size calculated by an equivalent dose of donepezil patch could be rather large. Further optimization in formulation needs to be performed to find appropriate usability in clinical situations.

23 December 2024 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
LNLien Thi Ngo
Lien Thi Ngo
WJWoojin Jung
Woojin Jung
TBTham Thi Bui
Tham Thi Bui
HYHwi-yeol Yun
Hwi-yeol Yun
Jung-woo ChaeJung-woo Chae
Jung-woo Chae
JMJeremiah D. Momper
Jeremiah D. Momper
Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity. Therefore, the prediction of drug–drug interactions (DDIs) and estimation of dosing requirements for concomitantly administered drugs is imperative. In this study, we aimed to develop a physiologically‐based PK (PBPK) model for RTV using the PK‐sim® software platform. A total of 13 clinical PK studies of RTV covering a wide dose range (100 to 600 mg including both single and multiple dosing), and eight clinical DDI studies with RTV on CYP3A and P‐gp substrates, including alprazolam, midazolam, rivaroxaban, clarithromycin, fluconazole, sildenafil, and digoxin were used for the model development and evaluation. Chronopharmacokinetic differences (between morning vs. evening doses) and limitations in parameter estimation for biochemical processes of RTV from in vitro studies were incorporated in the PBPK model. The final developed PBPK model predicted 100% of RTV AUClast and Cmax within a twofold dimension error. The geometric mean fold error (GMFE) from all PK datasets was 1.275 and 1.194, respectively. In addition, 97% of the DDI profiles were predicted with the DDI ratios within a twofold dimension error. The GMFE values from all DDI datasets were 1.297 and 1.212, respectively. Accordingly, this model could be applied to the prediction of DDI profiles of RTV and CYP3A substrates and used to estimate dosing requirements for concomitantly administered drugs.